Teva Pharmaceuticals has been awarded a significant contract worth $64.35 million by the Department of Veterans Affairs for Glatiramer injections. This contract is directly related to TEVA and is expected to have a positive impact on the company's revenues in the short term. The importance of this news for investors is high, as it indicates potential growth in the company's revenues. The confidence in this analysis is 90% due to the direct mention of TEVA and the substantial contract value.